Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer (NSCLC), confirmed through laboratory testing of a tissue sample.
- People who are 18 years of age or older.
- People whose lung cancer is at an advanced or metastatic stage (stage IV), meaning it has spread.
- People who have not yet received any treatment for this cancer.
- People whose cancer is considered eligible for a type of first-line treatment called an immune checkpoint inhibitor, as determined by their treating doctor.
- People whose cancer can be measured on a CT scan using a standard measurement system called RECIST 1.1.
- People whose tumor biopsy has been tested for a protein called PD-L1.
- People whose cancer does not have specific gene changes known as ALK or EGFR alterations.
- People who have enough tumor tissue available for a type of detailed genetic testing called NGS (requiring 7 slides).
- People with a good general level of physical functioning (rated 0 or 1 on a standard performance scale, meaning fully active or able to carry out light activities).
- People who have given their signed agreement to take part in the trial.
Who may not be able to join:
- People who are not affiliated with the French social security system.
- People who are under a legal protection order (such as guardianship or similar legal arrangements).
- People who are pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nicolas GIRARD, PR, INSTITUT CURIE - Medical Oncology
Phone: 01 56 24 56 49
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ctDNA variation of the prominent mutant allele variation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.